Organiser: Prof. Michel Kazatchkine (FR), UN Secretary General's Special Envoy on HIV/Aids in Eastern Europe & Central Asia; Member of the Global Commission on Drug Policy; Former Executive Director, The Global Fund, Member of Euroscience. Aidan Gilligan (IRL), Founder & CEO, SciCom – Making Sense of Science.

Monday 25th July, 2016: 12h50 – 15h20
ESOF 2016 MANCHESTER

Session Abstract:

Drug use and possession are banned in 150 countries worldwide with 33 countries and territories retaining the death penalty and 1,000+ drug-offence executions annually. This international drug enforcement regime has failed to reduce the use and harm caused by drugs. In response, the UN Secretary General called for a special session on drugs at the UN General Assembly in 2016 – the first in nearly two decades. As the fragile consensus supporting prohibition slowly unravels, experts gauge what might happen next.

Organiser & Moderator: Clive Cookson (UK), Science Editor, Financial Times & Member, IMMC ESOF 2016. Aidan Gilligan (IRL), Founder & CEO, SciCom – Making Sense of Science & Vice-Chair, IMMC ESOF 2016 / GB Euroscience.

Tuesday 26th July, 2016: 14h15 – 15h30
ESOF 2016 MANCHESTER

Session Abstract:

Which matters most – an individual’s right to be forgotten or society’s right to know about their past? For example, if a murderer or paedophile serves a prison sentence, why should his or her neighbours be aware? Who should decide if a request for delisting and deletion of information, videos or photographs from a publicly available database is valid? Does it risk decreasing the quality of the Internet through censorship or even rewriting history?

Organiser: Dr Thomas Hartung (DE), Johns Hopkins University, Bloomberg School of Public Health. Aidan Gilligan (IRL), Founder & CEO, SciCom – Making Sense of Science.

Tuesday 26th July, 2016: 17h10 – 18h25
ESOF 2016 MANCHESTER

Session Abstract:

Like it or not, animal testing is key to public health. But doubts are growing – not only for ethical reasons, but also in terms of costs, long study times, and a lack of accuracy – rabbit skin is not human skin. Billions are spent on compulsory testing at circa €20 million for a pesticide or €10 million for a new drug. Yet, the majority of the 7,000 flavours in e-cigarettes, the 5,000 additives in food or the 3,000 fragrances we use every day have never been tested.

Organiser: Dr. Thomas Hartung (DE), Professor of Pharmacology and Toxicology, University of Konstanz, Germany & Johns Hopkins Bloomberg School of Public Health, Dept. of Environmental Health Sciences & Molecular Microbiology and Immunology. Co-organiser: Aidan Gilligan (IRL), Founder, CEO SciCom – Making Sense of Science & Euroscience.

Wednesday 27th July, 2016: 12h50 – 14h05
ESOF 2016 MANCHESTER

Session Abstract:

Independent clinical trials are fundamental to improving the results, safety and cost-effectiveness of our health care systems. Yet, the exorbitant costs and acceptance hurdles involved often limit their scope to new products i.e. they are profit-driven and industry-led. Money matters. Important clinical interventions, surgery, physiotherapy, rehabilitation, public health measures etc. are of less interest to commercial sponsors seeking the lucrative benefits of primarily drug and device authorisation. While investigator-driven studies now find some support in the US, EU and elsewhere, they just cannot match the resources available for commercial clinical trials.